Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MARCH HIV switch study
ACTRN12611000816954Phase 4Recruiting
- Sponsor
- The Kirby Institute
- Start
- Aug 2011
- Modality
- Small Molecules
- Countries
- 13
01
Overview
Phase 4, randomised, open-label trial of maraviroc in human immunodeficiency virus infection (HIV) (3 arms), sponsored by The Kirby Institute. Primary endpoint: Virologic suppression at week 48. Started Aug 2011; status: recruiting.
02
Drugs
maraviroc
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on ACTRN12611000816954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12611000816954.